Clinical Trial Update: Monthly Dosing of Atacicept in IgAN [Phase 2]

View source ↗

Summary

A Phase 2 trial of atacicept for IgA nephropathy is ongoing but not currently recruiting, per Vera Therapeutics' update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Atacicept (atacicept)

Snippet

Sponsor: Vera Therapeutics, Inc. | Conditions: IgA Nephropathy (IgAN), Berger Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING